Patents
Literature
132 results about "Immunodeficiency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunodeficiency is a state in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. Most cases of immunodeficiency are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection, extremes of age, and environmental factors, such as nutrition. In the clinical setting, the immunosuppression by some drugs, such as steroids, can be either an adverse effect or the intended purpose of the treatment. Examples of such use is in organ transplant surgery as an anti-rejection measure and in patients suffering from an overactive immune system, as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency. A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised person may be particularly vulnerable to opportunistic infections, in addition to normal infections that could affect everyone. Immunodeficiency also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones.
TGFβ signal convertor
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC
Application of vitamin K3 in preparation of medicine for treating psoriasis
PendingCN121401245AOrganic active ingredientsDermatological disorderAntiendomysial antibodiesVitamin K3
The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.
Owner:SUN YAT SEN UNIV
Dimerizing agent regulated immunoreceptor complexes
The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC
Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
PCT designated stage expiredWO2025015586A1Organic active ingredientsGroup 5/15 element organic compoundsTLR8Disease
Provided herein are novel drug-linker conjugates and antibody-drug conjugates of imidazoquinoline amine derivatives, which have agonistic activities towards Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, as well as pharmaceutical compositions and methods of treatment thereof for certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, cancer and immunodeficiency).
Owner:CANWELL BIOTECH LTD
Colu virus attenuated strain and application thereof
PendingCN121628844ASsRNA viruses negative-senseViral antigen ingredientsImmunodeficiencyHumoral immune reaction
The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Lactobacillus casei MY01 with effect of improving immunity and application of lactobacillus casei MY01
The invention belongs to the technical field of probiotics, and particularly relates to a lactobacillus casei MY01 strain with an effect of improving immunity and application of the lactobacillus casei MY01 strain. A new Lactobacillus casei MY01 strain is separated from feces of a healthy infant in Guangzhou city, Guangdong province, a zebra fish immunosuppression model is constructed, and research finds that the Lactobacillus casei MY01 strain can increase the number of macrophages, neutrophil and T cells, increase the expression quantity of if n phi 1, if n phi 3 and if ng genes, inhibit the activity of angiotensin converting enzyme, inhibit the expression quantity of if n is greater than 1, and inhibit the expression quantity of if n is greater than 1, so that the new Lactobacillus casei MY01 strain can be used for preparing the new Lactobacillus casei MY01 strain. The potential effect of improving the immunity is realized. Therefore, the strain can be used in the field of medicine, and can be used for developing immunomodulatory drugs and assisting in treating immunosuppression related diseases, such as chronic infection and tumors; the method can also be applied to the health care product industry, develops health care products for enhancing immunity, and helps people to improve autoimmunity and maintain a healthy state.
Owner:GUANGDONG WANWUYI BACTERIA BIOTECHNOLOGY CO LTD
Construction method and application of monkey pox virus infected immunodeficiency mouse model
PendingCN119120589Ashort preparation timelow costHydrolasesMicrobiological testing/measurementImmunodeficient mouse modelInterferon receptor
The invention relates to a construction method and application of a monkey pox virus infected immunodeficiency mouse model, and belongs to the technical field of gene engineering and virus infection. The invention provides a construction method of a monkey pox virus infected immunodeficiency mouse model, which comprises the following steps of: knocking out interferon I, interferon II and interferon III passages by using a CRISPR / Cas9 technology, specifically knocking out a mouse I type interferon receptor IFNAR, knocking out a mouse II type interferon receptor IFNGR and knocking out a mouse III type interferon receptor IFNLR. The mouse constructed by the method disclosed by the invention has the severe condition of infection of the monkey pox virus IIb branch, and can be used for screening medicines for treating infection of the monkey pox virus IIb subtype branch.
Owner:GUANGZHOU EIGHTH PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV
Boletus brownii xylan palmitate as well as preparation method and application thereof
The invention discloses boletus brownii xylan palmitate as well as a preparation method and application thereof. The boletus brownii xylan palmitate is xylan palmitate which is formed by alpha-(1-> 4)-xylose as a main chain, alpha-(1->)-glucose as a branch chain and palmitic acid molecules through ester bonds. The invention further discloses a preparation method of the boletus brownii xylan palmitate and application of the boletus brownii xylan palmitate in the aspect of immunoregulation. The boletus brownii xylan palmitate can be used as a dietary supplement or a food additive for immunodeficiency patients and tumor patients.
Owner:YANTAI UNIV
THROMBOPOIETIN RECEPTOR (Mpl) KNOCKOUT IMMUNODEFICIENT RODENT
To provide an immunodeficient rodent in which human platelets or the like differentiate and increase.SOLUTION: An immunodeficient rodent in which a thrombopoietin (TPO) receptor (Mpl) gene is knocked out.SELECTED DRAWING: None
Owner:CENT INST FOR EXPERIMENTAL ANIMALS
Application of LYG1 in preparation of medicine for treating immune-related diseases
PendingCN119607182Areduce the ratioAntibacterial agentsPeptide/protein ingredientsAutoimmune conditionImmunodeficiency disease
The invention discloses an application of a cytokine LYG1 in preparation of a medicine for treating immune-related diseases. According to the present invention, the regulation effect and the mechanism of LYG1 in Tfh cells and cGVHD are deeply researched, such that the following important research results are obtained: the deletion of LYG1 inhibits the Tfh cell differentiation and the expression of characteristic molecules (BCL6, CXCR5, ICOS, TOX2 and the like), and the GC-B cell ratio and the antibody generation are reduced; the invention can be used for drugs and vaccines for autoimmune diseases such as cGVHD, immunodeficiency diseases and infectious diseases.
Owner:PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)
Multipartite receptor and signaling complexes
PendingUS20250242024A1Peptide/protein ingredientsAntibody mimetics/scaffoldsAntigenAutoimmune condition
The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC
Drug conjugates of imidazo quinoline amine derivatives, compositions and methods thereof
The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).
Owner:CANWELL BIOTECH LTD
Anti-CD28 antibodies and uses thereof
The invention relates to an anti-CD28 antibody or an antigen binding fragment thereof, and a multispecific antibody constructed based on the antibody or the antigen binding fragment thereof, such as an anti-CD3 * CD28 bispecific antibody and an anti-tumor associated antigen (TAA) * CD3 * CD28 trispecific antibody. The invention also relates to a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a cell comprising the nucleic acid molecule, a pharmaceutical composition comprising the antibody or the antigen binding fragment thereof, and application of the antibody or the antigen binding fragment thereof, especially application of the antibody or the antigen binding fragment thereof in treating tumors or immunodeficiency diseases.
Owner:CYTOCARES (SHANGHAI) INC
Fusion protein of anti-TIGIT antibody and IL2 or variant and application thereof
PendingCN119421903APeptide/protein ingredientsAntibody mimetics/scaffoldsAntiendomysial antibodiesAntigen Binding Fragment
The present disclosure provides a fusion protein of an anti-TIGIT antibody and IL2, or a variant thereof, and an application thereof. Specifically, the present disclosure provides a fusion protein comprising: (a) a first polypeptide comprising an anti-TIGIT antibody or an antigen-binding fragment thereof; (b) a second polypeptide comprising interleukin-2 (IL-2) or a variant thereof having lymphocyte growth promoting activity wherein the second polypeptide is fused to the first polypeptide. The invention further provides application of the fusion protein in forward regulation of immune cell activity and / or improvement of immune response. And / or to treat cancer, an immunodeficient or inflammatory disease, or an infectious disease.
Owner:SHANGHAI CELGEN BIO PHARMA CO LTD
Cpg oligodeoxynucleotide with regulating body immune capacity and its application
ActiveCN118909014BOrganic active ingredientsAntibacterial agentsImmunodeficiencyImmune dysregulation
The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.
Owner:NANJING JSIAMA BIOPHARMACEUTICALS LTD
Hemoglobin-related gene for diagnosing immune status and use thereof
PCT designated stageWO2026005512A1Microbiological testing/measurementBiological testingImmunodeficiencyRelated gene
The present invention relates to a composition for diagnosing immunodeficiency or a method for providing information for diagnosis thereof. By using the composition and the method according to one aspect, it is possible to simply and effectively diagnose immune-deficient conditions such as immunosuppression or immune paralysis.
Owner:SUNG KWANG MEDICAL FOUND
AAVR knockout mouse in combination with human liver chimerism and methods of use and production of the same
PendingUS20260007122A1Compounds screening/testingCell receptors/surface-antigens/surface-determinantsImmune compromisedKnockout animal
The present disclosure provides an immunodeficient or immune-impaired chimeric non-human animal with a deletion or impairment of adeno-associated virus receptor (AAVR), comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to evaluate transduction efficiency of adeno-associated viruses (AAV), and determine mechanism of inhibition / modification of AAV transduction in human hepatocytes.
Owner:AVACHROME INC
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
InactiveEP4516807A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseBone marrow failure
The present invention relates to compositions comprising at least one monoclonal antibody directed against a protein expressed on hematopoietic stem cells for use in a method of providing stem cell engraftment in a subject. The invention also relates to such compositions for use in a method of treatment of hereditary anemias, bone marrow failures, immunodeficiencies and metabolic diseases. The method comprises at least one conditioning step comprising the simultaneous or subsequent administration of the composition comprising at least one monoclonal antibody directed against a protein expressed on hematopoietic stem cells and at least one hematopoietic stem cell mobilization agent to the subject.
Owner:CONSORCIO CENT DE INVESTIGACION BIOMEDICA & RED M P +2
Method of induction of immune cells into a memory-like state
PCT designated stageWO2025166096A1Genetically modified cellsBlood/immune system cellsAutoimmune conditionLymphocyte
The present invention pertains to the field of cellular immunotherapy. More precisely, it is directed to therapeutic interventions against cancer, immunodeficiency, infectious diseases, and autoimmune conditions utilizing human memory-like cytotoxic lymphocytes, including T cells, Natural Killer (NK) cells, Natural Killer T (NKT) cells, monocytes and other relevant cell types. Disclosed are methods for the isolation and induction of these cells into a memory-like state, which can find application in therapeutic contexts as well as in non-therapeutic contexts, such as in research endeavors.
Owner:INNDURA THERAPEUTICS INC
Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
PendingJP2026010043AInorganic boron active ingredientsEnergy modified materialsNeutron captureImmunodeficiency
To provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and neutron capture therapy (NCT).SOLUTION: Disclosed herein are borylated amino acid ("BAA") compositions and methods of making BAAs. Accordingly, BAAs can be administered to patients as neutron capture agents and can provide methods of treating cancer, immune disorders, and other diseases by utilizing neutron capture therapy modalities. The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the present invention relates to borylated amino acid ("BAA") or ("BAAs") compositions that can be used as a vehicle for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases.SELECTED DRAWING: None
Owner:TAE LIFE SCIENCES LLC
Non-human autoimmune disease model animal, myositis model animal, method for producing same, and use thereof
PCT designated stageWO2025258683A1Microbiological testing/measurementBlood/immune system cellsImmunologic disordersPeripheral blood mononuclear cell
Provided is a non-human autoimmune disease model animal derived from an immunodeficient non-human animal as a pathologic model animal in which symptoms of an autoimmune disease are more faithfully reproduced, wherein peripheral blood mononuclear cells (PBMCs) derived from a heterologous animal subjected to CD8-positive T cell removal treatment are transfected, and symptoms of an autoimmune disease are exhibited.
Owner:TANABE PHARMA CORP
New application of BCAS2 gene
The invention provides a novel application of a BCAS2 gene, and belongs to the field of biomedical technology and diagnosis. According to the present invention, by detecting the expression condition of the BCAS2 gene or screening the T-G mutation occurring in the sequence 3 'UTR region of the BCAS2 gene, the relevance between the BCAS2 and the HIGM1 patient pathogenesis is revealed, the clinical diagnosis category of the HIGM1 disease is hopefully widened to a great extent, and the diagnosis accuracy is significantly improved; meanwhile, the discovery is expected to open up a brand new target direction for diagnosis and treatment of other immunodeficiency diseases.
Owner:CHINA AGRI UNIV
Novel latilactobacillus curvatus strain having immunoenhancing efficacy and immunoenhancing composition comprising same
PCT designated stageWO2026075443A1BacteriaAnimal feeding stuffPhosphorylationNatural Killer Cell Inhibitory Receptors
The present invention relates to a novel Latilactobacillus curvatus strain WiKim0169 having immunoenhancing efficacy, and an immunoenhancing composition comprising same. In the present invention, it was found that the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, significantly increases splenic NK cell activity and increases the production of inflammatory mediators, immunoglobulins, and cytokines, thereby alleviating immunosuppressive responses. In addition, it was confirmed that the Latilactobacillus curvatus strain WiKim0169 has an effect of alleviating immune dysfunction by increasing the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in splenic tissue and increasing the phosphorylation levels of NF-κB and IκBα. Therefore, according to the present invention, the composition comprising the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, as an active ingredient is expected to be usefully employed as a pharmaceutical and functional food composition for immunoenhancement.
Owner:PHARMSVILLE
Tgfbeta signal convertor
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC
Pharmaceutical composition based on phellinus igniarius and immune globulin IgD and preparation method thereof
InactiveCN119607197AEasy to adjustfunction increaseAntipyreticAnalgesicsBiotechnologyAutoimmune condition
The invention relates to the technical field of medicine and biology, and discloses a medicinal composition based on phellinus igniarius and immune globulin IgD. The medicinal composition comprises the following components in percentage by weight: 60-80% of phellinus igniarius extract, which contains more than or equal to 85% of polysaccharide and more than or equal to 60% of triterpenoids; 10%-30% of immune globulin IgD; 3%-10% of an astragalus extract; 1%-5% of an earthworm extract; 2%-8% of a ginseng extract; 1%-3% of a stabilizer comprising glycerin, sucrose or a combination thereof; 0%-5% of a forming agent which comprises medicinal starch or other medicinal excipients; the pharmaceutical composition can be prepared into capsules, granules or liquid preparations, and is used for regulating immune functions and treating immunodeficiency diseases, chronic inflammatory diseases and autoimmune diseases. According to the present invention, the phellinus igniarius extract high-purity polysaccharide and the triterpenoid are combined with the immune globulin IgD, and the milkvetch root extract, the earthworm extract and the ginseng extract are supplemented to construct the synergistic effect pharmaceutical composition so as to significantly enhance the immunoregulation and anti-inflammatory functions;
Owner:丁高产
Anti-CD28 antibody and use thereof
Provided are an anti-CD28 antibody or an antigen-binding fragment thereof, and a multi-specific antibody constructed on the basis of the antibody or the antigen-binding fragment thereof. The multi-specific antibody comprises an anti-CD3×CD28 bispecific antibody and an anti-tumor-associated antigen (TAA)×CD3×CD28 trispecific antibody. Further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a cell comprising the nucleic acid molecule, a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and the use of the antibody or the antigen-binding fragment thereof, in particular for the treatment of tumors or immunodeficiency diseases.
Owner:CYTOCARES (SHANGHAI) INC
Mouse gastric adenocarcinoma cell line MPC as well as construction method and application thereof
PendingCN120442547AMicrobiological testing/measurementMicroorganism based processesCancer cellMouse tumor
The invention discloses a mouse gastric adenocarcinoma cell line MPC as well as a construction method and application thereof, and belongs to the technical field of preparation of tumor cell lines and tumor models. The mouse gastric adenocarcinoma cell strain MPC is preserved in China Center for Type Culture Collection, has Cdh1 and Tp53 gene mutations at the same time, has stable cell biological characteristics and typical adenocarcinoma characteristics, can form tumors in immunodeficient and normal immune mice, can be used for preparing a mouse tumor model for occurrence, development and metastasis of gastric cancer, and has a good application prospect. The method is applied to important researches such as molecular biology, cytobiology, detection kit development, new drug research and development and the like.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Application of GPAAV-CBA-H_TP53(P53)-WPRE plasmid
The application of the GPAAV‑CBA‑H_TP53(P53)‑WPRE plasmid of the present invention belongs to the field of genetic engineering technology. The application of the GPAAV‑CBA‑H_TP53(P53)‑WPRE plasmid in the preparation of hypoglycemic drugs. The plasmid has the effect of lowering blood sugar in immunodeficient subjects, but has no effect on non-immunodeficient subjects. The immunodeficiency type is a thymus-deficient type. The present invention has the following advantages: the adeno-associated virus packaged with the GPAAV‑CBA‑H_TP53(P53)‑WPRE plasmid has the effect of lowering blood sugar in immunodeficient subjects, but has no effect on non-immunodeficient subjects, and the hypoglycemic effect of the adeno-associated virus packaged with the plasmid is correlated with the immunodeficiency of the subject.
Owner:SHENZHEN PUSIDA GENE TECH CO LTD
Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating myelodysplastic syndrome
The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating myelodysplastic syndrome and related complications thereof. The traditional Chinese medicine composition comprises sculellaria barbata, astragalus membranaceus, angelica sinensis, nightshade, radix curcumae, red ginseng, duchesnea indica, saussurea involucrata, cyclea verticillata and salvia miltiorrhiza. The traditional Chinese medicine composition has a good prevention and treatment effect on myelodysplastic syndrome and related complications thereof, can effectively inhibit proliferation of hematological tumor cells, and also can inhibit proliferation of the myelodysplastic syndrome by increasing the hemoglobin level, reducing the inflammatory cytokine level and reducing the proportion of peripheral blood T cells. Anemia, inflammation and low immune function caused by the myelodysplastic syndrome can be treated. The invention provides an effective strategy for prevention or treatment of myelodysplastic syndrome and related complications thereof, and provides a new direction for application of the traditional Chinese medicine composition.
Owner:GUIYANG XINTIAN PHARMA CO LTD +1
Multisite receptors and signaling complexes
The present invention provides adoptive T cell therapy with improved structures for targeting antigens and recruiting multimeric immune signaling complexes to treat, prevent, or ameliorate at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease, and immune deficiency, or conditions associated therewith. The present disclosure relates generally to engineered immune receptor complexes capable of recognizing a target antigen and recruiting and activating natural or transgenic immune receptor signaling complexes, e.g., T cell receptor (TCR) signaling complexes, polynucleotides and polypeptides encoding same, compositions thereof, and methods of making and using same to treat a disorder or disease (e.g., cancer or autoimmunity).
Owner:REGENERON PHARMACEUTICALS INC